Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

M. Fevzi Ozkaynak1*, Andrew L. Gilman2, Wendy B. London3, Arlene Naranjo4, Mitchell B. Diccianni5, Sheena C. Tenney4, Malcolm Smith6, Karen S. Messer5, Robert Seeger7, C. Patrick Reynolds8, L. Mary Smith9, Julie R. Park11, Paul M. Sondel13 and Alice L. Yu5,14*, for the Children’s Oncology Group (COG)

1 New York Medical College, Valhalla, NY, United States, 2 Levine Children’s Hospital, Charlotte, NC, United States, 3 Dana Farber Cancer Institute and Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States, 4 Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United States, 5 Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States, 6 National Cancer Institute, Bethesda, MD, United States, 7 Children’s Hospital Los Angeles, University Southern California, Los Angeles, Los Angeles, CA, United States, 8 Texas Tech University Health Sciences Center, Lubbock, TX, United States, 9 United Therapeutics, Silver Spring, MD, United States, 10 St. Jude’s Children’s Research Hospital, Memphis, TN, United States, 11 Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA, United States, 12 Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 13 University of Wisconsin Carbone Cancer Center, Madison, WI, United States, 14 Institute of Stem Cell and Translational Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Keywords: neuroblastoma, immunotherapy, anti-GD2 chimeric antibody, cytokines, safety, cytokine biomarkers

A corrigendum on

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, et al. Front Immunol (2018) 9:1355. doi: 10.3389/fimmu.2018.01355

In the original article, we neglected to include the funder NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation.

The revised “Funding” should read: This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex’s Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation and COG SDC grant U10CA180899.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Ozkaynak, Gilman, London, Naranco, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Shulkin, Parisi, Maris, Park, Sondel and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.